BR112016013157A2 - peptídeos resistentes à protease - Google Patents

peptídeos resistentes à protease

Info

Publication number
BR112016013157A2
BR112016013157A2 BR112016013157A BR112016013157A BR112016013157A2 BR 112016013157 A2 BR112016013157 A2 BR 112016013157A2 BR 112016013157 A BR112016013157 A BR 112016013157A BR 112016013157 A BR112016013157 A BR 112016013157A BR 112016013157 A2 BR112016013157 A2 BR 112016013157A2
Authority
BR
Brazil
Prior art keywords
peptides
protease resistant
resistant peptides
incorporation
alpha
Prior art date
Application number
BR112016013157A
Other languages
English (en)
Portuguese (pt)
Inventor
Revell Jefferson
Bednarek Maria
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of BR112016013157A2 publication Critical patent/BR112016013157A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/605Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112016013157A 2013-12-13 2014-12-10 peptídeos resistentes à protease BR112016013157A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915662P 2013-12-13 2013-12-13
PCT/EP2014/077240 WO2015086686A2 (en) 2013-12-13 2014-12-10 Protease resistant peptides

Publications (1)

Publication Number Publication Date
BR112016013157A2 true BR112016013157A2 (pt) 2017-09-26

Family

ID=52021207

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016013157A BR112016013157A2 (pt) 2013-12-13 2014-12-10 peptídeos resistentes à protease

Country Status (11)

Country Link
US (1) US20160318987A1 (enExample)
EP (2) EP3080153A2 (enExample)
JP (1) JP2017502003A (enExample)
KR (1) KR20160098406A (enExample)
CN (1) CN105849123A (enExample)
AU (1) AU2014363547A1 (enExample)
BR (1) BR112016013157A2 (enExample)
CA (1) CA2933405A1 (enExample)
MX (1) MX2016007407A (enExample)
SG (1) SG10201805039UA (enExample)
WO (1) WO2015086686A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
AU2016343775B2 (en) 2015-10-28 2021-07-29 Tufts Medical Center Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
KR20190017017A (ko) 2016-06-09 2019-02-19 메디뮨 리미티드 프로테아제-내성 모노-지질화된 펩타이드
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
ES2980707T3 (es) 2018-04-05 2024-10-02 Sun Pharmaceutical Ind Ltd Nuevos análogos de GLP-1
JP7736315B2 (ja) * 2020-03-31 2025-09-09 アンタロス メディカル アクティエボラーグ イメージング及び治療目的のキレート部分を含む選択的gip受容体アゴニスト
IL303578A (en) * 2020-12-16 2023-08-01 Medimmune Ltd Polypeptides and their uses
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的glp—1及升糖素雙重激動肽

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1495198A (zh) * 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
CA2641053A1 (en) * 2006-02-08 2007-08-16 Lonza Ag Synthesis of glucagon-like peptide
EP2021014A1 (en) * 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
US20090318353A1 (en) * 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
CA2707448C (en) * 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
ES2354488T3 (es) * 2008-04-18 2011-03-15 F. Hoffmann-La Roche Ag Alfa-n-metilación de aminoácidos.
US20120264685A1 (en) * 2009-10-22 2012-10-18 Rajesh Bahekar Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
US20130143800A1 (en) * 2011-11-07 2013-06-06 Research Development Foundation Combination therapies to treat diabetes
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法

Also Published As

Publication number Publication date
CN105849123A (zh) 2016-08-10
JP2017502003A (ja) 2017-01-19
MX2016007407A (es) 2016-12-12
WO2015086686A2 (en) 2015-06-18
SG10201805039UA (en) 2018-07-30
KR20160098406A (ko) 2016-08-18
CA2933405A1 (en) 2015-06-18
EP3415526A1 (en) 2018-12-19
EP3080153A2 (en) 2016-10-19
WO2015086686A3 (en) 2015-10-29
AU2014363547A1 (en) 2016-06-30
US20160318987A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
BR112016013157A2 (pt) peptídeos resistentes à protease
CY1125302T1 (el) Συναγωνιστες γλυκαγονης και glp-1 για την αγωγη της παχυσαρκιας
CR20130667A (es) Composiciones que contienen, mètodos que involucran, y usos derivados de dolastatina unidos a aminoàcidos no naturales
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
BR112018007017A2 (pt) polipeptídeos
ECSP16012693A (es) Polipéptido para la escisión hidrolítica de la zearalenona y/o derivados de la zearalenona, polinucleótido aislado de la misma y polipéptido que contiene aditivo, uso y procedimiento de los mismos
MX365157B (es) Peptidos y composiciones para el tratamiento de daños de las articulaciones.
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
MX2015015188A (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
EA201692288A1 (ru) Способ получения фосфорсодержащих циангидринов
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
BR112015024860A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
DOP2016000211A (es) Pirazinas moduladoras de gpr6
BR112019005886A2 (pt) tratamento com água de material lipídico
CO2018010286A2 (es) Método para la purificación de proteínas
CL2017001633A1 (es) Método de manufactura de proteína.
BR112016018594B8 (pt) Método para produção do derivado de 2-aciliminopiridina
UA118269C2 (uk) Промисловий спосіб синтезу уліпристалу ацетату і його 4'-ацетильного аналога
MX2015010006A (es) Purificacion de proteinas mejorada a traves de una etapa de desglicosilacion.
BR112016007816A2 (pt) composições peptídicas inovadoras
CO2018001307A2 (es) Un proceso mejorado para la preparación de tetrofosmina o su sal de adición de ácido
NZ733839A (en) Amino acid and peptide conjugates and conjugation process

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]